Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 254 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: retinyl palmitate Clear all
Completed Not applicable Interventional

Prevention of Malnutrition in Children With Sickle Cell Disease

NCT06397118
View directory record Official record
Conditions
Sickle Cell Disease, Malnutrition
Interventions
Maternal Nutrition Education, Standard Care
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
6 Months to 18 Months
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 18, 2026, 9:52 AM EDT
Completed Phase 2 Interventional Results available

Intralesional Vitamin D Injection for Treatment of Common Warts

NCT04278573
View directory record Official record
Conditions
Warts
Interventions
Vitamin D3, Placebo
Drug
Lead sponsor
Stephen P. Merry
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 18, 2026, 9:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

NCT04303169
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab, Vibostolimab, Gebasaxturev, MK-4830, Favezelimab + Pembrolizumab, ATRA
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 18, 2026, 9:52 AM EDT
Completed Phase 1 Interventional Results available

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

NCT01175356
View directory record Official record
Conditions
Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, External Beam Radiation Therapy, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Intensity-Modulated Radiation Therapy, Iobenguane I-131, Isotretinoin, Laboratory Biomarker Analysis, Melphalan, Pharmacological Study, Questionnaire Administration, Therapeutic Conventional Surgery, Topotecan Hydrochloride, Vincristine Sulfate
Radiation · Procedure · Drug + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 18, 2026, 9:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Combinatorial Nutritional Supplementation on Immune Function in Healthy Older Adults

NCT02876315
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
Redoxon VI, placebo
Dietary Supplement
Lead sponsor
Oregon State University
Other
Eligibility
55 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 18, 2026, 9:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy Subjects

NCT01858935
View directory record Official record
Conditions
Healthy
Interventions
ND-L02-s0201 Injection, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 18, 2026, 9:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nutritional Outcomes After Vitamin A Supplementation in Subjects With SCD

NCT03632876
View directory record Official record
Conditions
Sickle Cell Anemia in Children, Vitamin A Deficiency in Children
Interventions
retinyl palmitate
Dietary Supplement
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
9 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 18, 2026, 9:52 AM EDT
Completed Phase 2Phase 3 Interventional

Evaluation of Tretinoin Cream on the Integrity of Aged Forearm Skin

NCT07084116
View directory record Official record
Conditions
Skin Tear, Solar Purpura, Dermatoporosis
Interventions
Tretinoin 0.1% cream, Bland cream (non-drug)
Drug
Lead sponsor
James Thomas Pathoulas
Other
Eligibility
55 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 18, 2026, 9:52 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles

NCT01283464
View directory record Official record
Conditions
Photodamaged Skin, Wrinkles
Interventions
Retinol, Tretinoin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
35 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 18, 2026, 9:52 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris

NCT04883736
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tretinoin Gel Microsphere, 0.1%, RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1%, Placebo Control
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
973 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 18, 2026, 9:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Vitamin A Equivalence of Plant Carotenoids in Children

NCT00680212
View directory record Official record
Conditions
Vitamin A Deficiency
Interventions
dietary carotenoids, spinach, rice, and synthetic beta-carotene
Dietary Supplement
Lead sponsor
Tufts University
Other
Eligibility
6 Years to 8 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 18, 2009 · Synced Oct 18, 2026, 9:52 AM EDT
Completed Phase 2 Interventional Results available

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

NCT03786783
View directory record Official record
Conditions
Ganglioneuroblastoma, High Risk Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Dexrazoxane, Dinutuximab, Doxorubicin, Etoposide, External Beam Radiation Therapy, Isotretinoin, Melphalan, Sargramostim, Thiotepa, Topotecan, Vincristine
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 18, 2026, 9:52 AM EDT
Not listed Phase 2 Interventional

Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00514293
View directory record Official record
Conditions
Lung Cancer
Interventions
bexarotene, capecitabine, carboplatin, cisplatin, docetaxel, tretinoin
Drug
Lead sponsor
Raghu Nandan, M.D., Inc
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 18, 2026, 9:52 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A

NCT00346333
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Lutein, Cornstarch control
Drug · Dietary Supplement
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years to 60 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 18, 2026, 9:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Studying Different Formulations of SR13668 in Healthy Volunteers

NCT00896207
View directory record Official record
Conditions
Healthy, no Evidence of Disease
Interventions
Akt inhibitor SR13668
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 62 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Oct 18, 2026, 9:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Evaluation of the Photoallergy Potential of Atralin Gel

NCT00603772
View directory record Official record
Conditions
Healthy
Interventions
Atralin (tretinoin) gel, 0.05%
Drug
Lead sponsor
Coria Laboratories, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2008 · Synced Oct 18, 2026, 9:52 AM EDT
Completed Not applicable Interventional

Vitamin A Replacement in Patients Undergoing HSCT and Its Role on MBI-LCBI Rates

NCT03039257
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplant
Interventions
Vitamin A
Dietary Supplement
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 18, 2026, 9:52 AM EDT
Completed Phase 1 Interventional

Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis

NCT01582932
View directory record Official record
Conditions
Psoriasis
Interventions
Calcipotriene 0.005% Foam
Drug
Lead sponsor
Mayne Pharma International Pty Ltd
Industry
Eligibility
2 Years to 11 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
36
States / cities
Birmingham, Alabama • Rogers, Arkansas • Encino, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 18, 2026, 9:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Phototoxity of Atralin (Tretinoin) Gel, 0.05%

NCT00604032
View directory record Official record
Conditions
Healthy
Interventions
Atralin (tretinoin) Gel, 0.05%
Drug
Lead sponsor
Coria Laboratories, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 28, 2008 · Synced Oct 18, 2026, 9:52 AM EDT
Completed Phase 3 Interventional Results available

S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia

NCT00492856
View directory record Official record
Conditions
Leukemia
Interventions
mercaptopurine, methotrexate, tretinoin
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
210
States / cities
Scottsdale, Arizona • Roseville, California • Sacramento, California + 135 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 18, 2026, 9:52 AM EDT
Completed Phase 2 Interventional

Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study

NCT00252005
View directory record Official record
Conditions
Deep-Vein Thrombosis
Interventions
Apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 90 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Albuquerque, New Mexico • Chapel Hill, North Carolina • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 18, 2026, 9:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face

NCT00952523
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tretinoin Facial Gel, Adapalene/Benzoyl Peroxide Facial Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2012 · Synced Oct 18, 2026, 9:52 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

NCT06047379
View directory record Official record
Conditions
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
Interventions
NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab
Drug
Lead sponsor
Neonc Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Beverly Hills, California • Glendale, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 18, 2026, 9:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fruit and Vegetable Juice Concentrate Effects on RBP4 and Antioxidant Capacity in Lean and Overweight 6-10 Year Old Boys

NCT00842543
View directory record Official record
Conditions
Obesity
Interventions
Fruit and Vegetable Juice Concentrate (FVJC), Placebo
Dietary Supplement
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
6 Years to 10 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 18, 2026, 9:52 AM EDT